Every Form 4 that Vanda Pharmaceuticals Inc. (VNDA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow VNDA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VNDA filings page.
McGuire Daniel Patrick reported acquisition or exercise transactions in this Form 4 filing.
Vanda Pharmaceuticals reported that SVP, General Counsel and Secretary Daniel Patrick McGuire received a grant of 80,000 shares of common stock underlying a restricted stock unit (RSU) award at no cash cost per share. His direct ownership after the grant is 109,982 common shares.
The RSU award vests in four equal annual installments beginning on June 4, 2027, as long as he remains continuously employed through each vesting date. Vested shares will be delivered on the first permissible trading day on or after each vesting date, making this a routine equity-based compensation grant rather than an open-market trade.
Chrousos Phaedra reported acquisition or exercise transactions in this Form 4 filing.
Vanda Pharmaceuticals director Phaedra Chrousos received a grant of 41,600 shares of Common Stock in the form of time-based restricted stock units. The award was granted at no cash cost per share and is part of her equity compensation.
All 41,600 RSU shares will vest on June 4, 2027, provided she continues to serve the company through that date. Following this grant, she directly holds 164,950 shares of Vanda Pharmaceuticals common stock.
Duncan Charles Cliff reported acquisition or exercise transactions in this Form 4 filing.
Vanda Pharmaceuticals director Charles Cliff received a grant of 41,600 shares of common stock in the form of time-based restricted stock units at no purchase price. These RSUs vest in full on June 4, 2027 if he remains in continuous service, bringing his direct holdings to 98,701 shares.
DUGAN RICHARD W reported acquisition or exercise transactions in this Form 4 filing.
Vanda Pharmaceuticals Inc. director Richard W. Dugan reported an equity compensation grant in the form of restricted stock units. On June 4, 2026, he was awarded 41,600 shares of common stock underlying a time-based RSU that vests 100% on June 4, 2027, contingent on continuous service. Following this grant, Dugan holds 219,054 shares of Vanda common stock directly.
Ward Anne Sempowski reported acquisition or exercise transactions in this Form 4 filing.
Vanda Pharmaceuticals Inc. director Anne Sempowski Ward received an equity award covering 41,600 shares of common stock in the form of time-based restricted stock units. The award was granted at no cash cost to her and is scheduled to vest in full on June 4, 2027, if she continues serving the company through that date. After this grant, she is reported as beneficially owning 160,667 shares of Vanda common stock directly.
Vanda Pharmaceuticals director Honore Tage received a grant of 41,600 shares of common stock through a restricted stock unit (RSU) award. The RSUs are time-based and will vest 100% on June 4, 2027, if Tage continues to provide service to the company through that date.
Following this grant, Tage directly holds 135,069 shares of Vanda Pharmaceuticals common stock. Because the shares were awarded as equity compensation at no cash cost, this filing reflects a compensation-related acquisition rather than an open-market purchase.
Mitchell Stephen Ray reported acquisition or exercise transactions in this Form 4 filing.
Vanda Pharmaceuticals Inc. director Mitchell Stephen Ray received a grant of 41,600 shares of Common Stock through a time-based restricted stock unit award at no cost. All RSUs will vest on June 4, 2027 if he remains in continuous service. Following this award, he directly owns 112,846 shares.
Vanda Pharmaceuticals Inc. director Mitchell Stephen Ray reported a charitable gift of 25,836 shares of Common Stock on a Form 4. The transaction used code "G" for a bona fide gift and carried a price of $0.00 per share, meaning no sale proceeds were received. After this donation to a charitable organization, Ray directly holds 71,246 shares of Vanda common stock. This is a non-market transaction and does not reflect open-market buying or selling activity.
Vanda Pharmaceuticals director Duncan Charles Cliff received an equity award of 57,101 shares of common stock in the form of restricted stock units (RSUs). The grant carries no cash exercise price and is recorded as a direct ownership position.
The RSU award is time-based and will vest in four equal annual installments, with the first vesting date on April 22, 2027, provided Cliff continues to serve the company through each annual vesting date. After this grant, his reported direct holdings from this award total 57,101 shares.
Vanda Pharmaceuticals Inc. executive Timothy Williams, its SVP & General Counsel, reported selling 42,434 shares of common stock on March 2, 2026. The shares were sold at a weighted average price of $8.2659 per share solely to satisfy tax obligations arising from the settlement of vested RSUs under the company’s RSU agreements. The transactions occurred in multiple trades at prices ranging from $8.085 to $8.81 per share. After these tax-related sales, Williams directly holds 377,450 shares of Vanda common stock.
Vanda Pharmaceuticals SVP, CFO & Treasurer Kevin Patrick Moran reported an open-market sale of 42,442 shares of common stock on March 2, 2026 at a weighted average price of $8.2659 per share. The filing explains these shares were sold to satisfy tax obligations arising from the settlement of vested RSUs under withholding provisions in the RSU agreements. After the sale, Moran directly held 411,380 common shares and indirectly held 635 additional shares through his wife. The sale occurred in multiple transactions at prices ranging from $8.085 to $8.81 per share.
Vanda Pharmaceuticals Inc. senior vice president and chief marketing officer Joakim Wijkstrom executed an open‑market sale of 30,800 shares of common stock on March 2, 2026 at a weighted average price of $8.2659 per share. The shares were sold to satisfy tax obligations arising from the settlement of vested restricted stock units under the company’s RSU agreements, rather than as a discretionary share sale. After these transactions, Wijkstrom directly held 333,469 shares of Vanda common stock. The trades were completed in multiple transactions at prices ranging from $8.085 to $8.81 per share.
Vanda Pharmaceuticals President and CEO Mihael Hristos Polymeropoulos reported an open-market sale of 156,235 shares of common stock at a weighted average price of $8.1734 per share. According to the disclosure, the shares were sold to satisfy tax obligations arising from the settlement of vested restricted stock units under RSU agreements.
After this transaction, the reporting person directly owned 2,704,496 shares of Vanda Pharmaceuticals common stock.
Vanda Pharmaceuticals Inc. senior vice president of business development Gunther Birznieks reported an open-market sale of 42,431 shares of common stock on March 2, 2026 at a weighted average price of $8.2659 per share. The shares were sold to satisfy tax obligations tied to the settlement of vested RSUs. After these transactions, he directly holds 494,197 shares. The sales occurred in multiple trades priced between $8.085 and $8.81 per share.
Vanda Pharmaceuticals director Honore Tage sold 30,000 shares of common stock in an open-market transaction at a price of $8.03 per share. After this sale, Tage directly owns 93,469 shares of Vanda Pharmaceuticals common stock.
Wijkstrom Joakim reported acquisition or exercise transactions in this Form 4 filing.
Vanda Pharmaceuticals senior vice president and chief marketing officer Joakim Wijkstrom received an equity grant covering 125,000 shares of common stock in the form of time-based restricted stock units (RSUs). These RSUs vest in four equal annual installments starting on March 1, 2027, contingent on his continued employment through each vesting date. After this award, his directly held common stock (including RSU-related shares as reported) totals 364,269 shares. The grant was recorded at a price of $0.00 per share, reflecting that it is a compensation award rather than an open-market purchase.
Birznieks Gunther reported acquisition or exercise transactions in this Form 4 filing.
Vanda Pharmaceuticals senior vice president of business development Gunther Birznieks reported an equity award in the form of 125,000 shares of common stock underlying a time-based restricted stock unit (RSU) grant. The RSUs vest in four equal annual installments, with the first vesting on March 1, 2027, as long as he remains continuously employed through each vesting date. Shares that vest will be delivered on the first permissible trading day defined in the RSU agreement. Following this grant, his directly held common stock position is 536,628 shares.
Williams Timothy reported acquisition or exercise transactions in this Form 4 filing.
Vanda Pharmaceuticals senior executive Timothy Williams received an equity award of 125,000 shares of common stock in the form of restricted stock units. These RSUs are scheduled to vest in four equal annual installments starting on March 1, 2027, contingent on his continued employment through each vesting date. After this grant, his directly held common stock reported in this filing totals 419,884 shares.
Vanda Pharmaceuticals Inc. reported that SVP, CFO & Treasurer Kevin Patrick Moran acquired 125,000 shares of common stock on February 18, 2026 through a time-based restricted stock unit (RSU) award granted at a price of $0.00 per share. The RSU represents common stock that will vest in four equal annual installments, with the first vesting on March 1, 2027, as long as he remains continuously employed through each vesting date. After this grant, he directly owns 453,822 shares of common stock, and there are an additional 635 shares reported as indirectly owned by his wife.
Polymeropoulos Mihael Hristos reported acquisition or exercise transactions in this Form 4 filing.
Vanda Pharmaceuticals President and CEO Mihael Hristos Polymeropoulos received an equity grant of 525,000 shares of common stock in the form of time-based restricted stock units. The award was recorded at a price of $0.00 per share, reflecting a compensatory grant rather than an open-market purchase.
The RSUs vest in four equal annual installments, with the first vesting date on March 1, 2027, as long as he remains continuously employed through each vesting date. Following this grant, his directly held common stock position is reported as 2,860,731 shares.